Samsung Medical Center-Lymphoma Cohort Study-II (SMC-LCS-II)
Prospective Observation Cohort Study of Malignant Lymphoma Patients
研究概览
地位
条件
详细说明
Although the cure rate of lymphoma has been increased due to the development of newer effective drugs, a substantial portion of patients is still suffered from relapse. Furthermore, the treatment-related morbidity is another factor which can make the treatment outcome worse in patients with lymphoma, especially elderly patients. Thus, this study is going to assess factors which may affect the treatment outcome and the risk of treatment-related morbidity.
1.Biologic factors associated with the aggressiveness of lymphoma
- molecular markers in serum, cytogenetic markers 2.Factors associated with the risk of treatment-related morbidity
- comorbidity, nutrition status, performance status, quality of life at diagnosis
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Seoul、大韩民国
- Samsung Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Patients who were diagnosed as lymphoma
- Over 19 years old
- Patients who agreed the enrollment of study
- Informed consent for sampling
Exclusion Criteria:
•Patients who do not want to join the study
学习计划
研究是如何设计的？
设计细节
- 观测模型：队列
- 时间观点：预期
队列和干预
团体/队列 |
|---|
|
Lymphoma
Lymphoma patients
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
All cause mortality
大体时间：5 years
|
Disease and non-disease-related mortality including treatment-related death
|
5 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Treatment response
大体时间：1 year
|
Response to primary and salvage treatment Revised response criteria for lymphoma should be used (J Clin Oncol 2007;25(5):579-586). Complete response: disappearance of all evidence of disease Partial response: regression of measurable disease and no new sites Stable disease: failure to attain CR/PR or PD Relapsed disease or Progressive disease: Any new lesion or increase by >=50% of previously involved sites from nadir |
1 year
|
|
Rate of occurrence of toxicity
大体时间：2 years from the start of the 1st therapy
|
Infectious complications and other toxicities
|
2 years from the start of the 1st therapy
|
|
Quality of life
大体时间：5 years
|
Change of quality of life
|
5 years
|
|
Biomarker development
大体时间：5 years
|
Biomarkers associated with treatment outcome
|
5 years
|
合作者和调查者
出版物和有用的链接
一般刊物
- Cho I, Lee H, Yoon SE, Ryu KJ, Ko YH, Kim WS, Kim SJ. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. BMC Cancer. 2020 Feb 13;20(1):120. doi: 10.1186/s12885-020-6612-2.
- Kim SJ, Hong M, Do IG, Lee SH, Ryu KJ, Yoo HY, Hong JY, Ko YH, Kim WS. Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator. Haematologica. 2015 Mar;100(3):e106-9. doi: 10.3324/haematol.2014.116087. Epub 2014 Dec 5. No abstract available.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.